Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (Ra Pharma) today announced the pricing of an underwritten public offering of 8,387,097 shares of its common stock, at a public offering price of $15.50 per share, before underwriting discounts and commissions. Ra Pharma also granted the underwriters a 30-day option to purchase up to an additional 1,258,064 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $130.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Ra Pharma.
Jefferies, BMO Capital Markets, and Stifel are acting as joint book-running managers for the offering. Guggenheim Securities is acting as lead manager, and Raymond James is acting as co-manager. The offering is expected to close on or about December 14, 2018, subject to customary closing conditions.
Ra Pharma intends to use the net proceeds from the offering, in addition to its existing cash resources, to fund the clinical development of zilucoplan, including the Phase 3 clinical program in gMG and the advancement of other pipeline programs, and for working capital and other general corporate and administrative expenses.
The securities described are being offered by Ra Pharma pursuant to a shelf registration statement on Form S-3 (No. 333-221266), including a base prospectus. The securities are being offered only by means of a prospectus. A preliminary prospectus supplement related to and describing the terms of the offering was filed with the SEC on December 11, 2018. The final prospectus related to the offering will be filed with the SEC and will be available on the SECs website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained, when available, from: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388 or by email at [email protected]; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, telephone: 800-414-3627, email: [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at 415-364-2720 or by email at [email protected].
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the completion and anticipated proceeds of the proposed offering. All such forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to fluctuations in our stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering, as well as the other factors discussed in the Risk Factors section in Ra Pharmas most recently filed Annual Report on Form 10-K, as well as other risks detailed in Ra Pharmas subsequent filings with the Securities and Exchange Commission. There can be no assurance that Ra Pharma will be able to complete the proposed public offering on the anticipated terms. All information in this press release is as of the date of the release, and Ra Pharma undertakes no duty to update this information unless required by law.
Natalie Wildenradt, 212-600-1902
David Rosen, 212-600-1902